BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 27650678)

  • 1. Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033).
    Davies KR; Brewster AM; Bedrosian I; Parker PA; Crosby MA; Peterson SK; Shen Y; Volk RJ; Cantor SB
    Breast Cancer Res; 2016 Sep; 18(1):93. PubMed ID: 27650678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis.
    Portschy PR; Kuntz KM; Tuttle TM
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25031308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness Analysis of Contralateral Prophylactic Mastectomy Compared to Unilateral Mastectomy with Routine Surveillance for Unilateral, Sporadic Breast Cancer.
    Keskey RC; LaJoie AS; Sutton BS; Kim IK; Cheadle WG; McMasters KM; Ajkay N
    Ann Surg Oncol; 2017 Dec; 24(13):3903-3910. PubMed ID: 29039025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and risks of contralateral prophylactic mastectomy in women undergoing treatment for sporadic unilateral breast cancer: a decision analysis.
    Lester-Coll NH; Lee JM; Gogineni K; Hwang WT; Schwartz JS; Prosnitz RG
    Breast Cancer Res Treat; 2015 Jul; 152(1):217-226. PubMed ID: 26062750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.
    Pesce C; Liederbach E; Wang C; Lapin B; Winchester DJ; Yao K
    Ann Surg Oncol; 2014 Oct; 21(10):3231-9. PubMed ID: 25081341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer.
    Wong SM; Freedman RA; Sagara Y; Aydogan F; Barry WT; Golshan M
    Ann Surg; 2017 Mar; 265(3):581-589. PubMed ID: 28169929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer.
    Zendejas B; Moriarty JP; O'Byrne J; Degnim AC; Farley DR; Boughey JC
    J Clin Oncol; 2011 Aug; 29(22):2993-3000. PubMed ID: 21690472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?
    Tesson S; Richards I; Porter D; Phillips KA; Rankin N; Costa D; Musiello T; Marven M; Butow P
    Breast; 2017 Feb; 31():233-240. PubMed ID: 27969575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer.
    Hegde JV; Wang X; Attai DJ; DiNome ML; Kusske A; Hoyt AC; Hurvitz SA; Weidhaas JB; Steinberg ML; McCloskey SA
    Clin Breast Cancer; 2018 Apr; 18(2):e205-e218. PubMed ID: 29050918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy.
    Davies KR; Cantor SB; Brewster AM
    Int J Womens Health; 2015; 7():181-7. PubMed ID: 25678823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition : Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology.
    Bjelic-Radisic V; Singer C; Tamussino K; Kölbl H; Petru E; Volgger B; Polterauer S; Oppelt P; Sevelda P; Bogner G; Marth C;
    Wien Klin Wochenschr; 2019 May; 131(9-10):233-236. PubMed ID: 30887224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.
    Rosenberg SM; Sepucha K; Ruddy KJ; Tamimi RM; Gelber S; Meyer ME; Schapira L; Come SE; Borges VF; Golshan M; Winer EP; Partridge AH
    Ann Surg Oncol; 2015 Nov; 22(12):3809-15. PubMed ID: 25930247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
    Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI
    J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of contralateral prophylactic mastectomy for prevention of contralateral breast cancer.
    Roberts A; Habibi M; Frick KD
    Ann Surg Oncol; 2014 Jul; 21(7):2209-17. PubMed ID: 24633665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting women's intentions for contralateral prophylactic mastectomy: An application of an extended theory of planned behaviour.
    Richards I; Tesson S; Porter D; Phillips KA; Rankin N; Musiello T; Marven M; Butow P
    Eur J Oncol Nurs; 2016 Apr; 21():57-65. PubMed ID: 26952679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer.
    Jagsi R; Hawley ST; Griffith KA; Janz NK; Kurian AW; Ward KC; Hamilton AS; Morrow M; Katz SJ
    JAMA Surg; 2017 Mar; 152(3):274-282. PubMed ID: 28002555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.
    Wang F; Amara D; Peled AW; Sbitany H; Foster RD; Ewing CA; Alvarado M; Esserman LJ
    Ann Surg Oncol; 2015 Oct; 22(10):3338-45. PubMed ID: 26215194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.
    King TA; Sakr R; Patil S; Gurevich I; Stempel M; Sampson M; Morrow M
    J Clin Oncol; 2011 Jun; 29(16):2158-64. PubMed ID: 21464413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.